CASI Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative therapeutics and pharmaceutical products, primarily in hematology oncology, organ transplant rejection, and autoimmune diseases across China, the United States, and global markets; its core products and pipeline include EVOMELA (melphalan for multiple myeloma conditioning prior to stem cell transplant), MARQIBO (liposomal vincristine for lymphomas), ZEVALIN (ibritumomab tiuxetan for non-Hodgkin lymphoma), CID-103 (anti-CD47 antibody), CNCT19 (CAR-T therapy), CB-5339, BI-1206 (anti-CD32B antibody), Thiotepa (chemotherapy agent), and ENMD-2076, with CID-103 currently advancing as an anti-CD38 monoclonal antibody targeting B memory cells, plasmablasts, and plasma cells for antibody-mediated rejection in organ transplants and autoimmune conditions like immune thrombocytopenia; founded in 1991 and headquartered in Beijing, China, the company recently received a $15 million private placement financing in June 2024 from investors including Venrock Healthcare Capital Partners, Foresite Capital, and Panacea, announced an updated non-binding $20 million proposal from CEO Dr. Wei-Wu He in April 2025 to acquire its entire China business operations and Asian rights (excluding Japan) to specific pipeline products including BI-1206, CID-103, and Thiotepa, reported second quarter 2025 financial results in August 2025 with cash reserves at $6.7 million as of June 30 amid strategic portfolio refinement retaining rights to CID-103 (Japan and non-Asian regions), EVOMELA, FOLOTYN, CNCT19, and CB-5339, and appealed a Nasdaq delisting determination in November 2025 while presenting a compliance plan.
Siga Technologies (NASDAQ:SIGA) and CASI Pharmaceuticals (NASDAQ:CASI) Financial Comparison
What Drove CASI Pharmaceuticals' 24% Rise After Hours?
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
CASI Pharmaceuticals Announces Changes in Board Governance
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
CASI Pharmaceuticals Appoints James Huang to Board of Directors
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program